Oslo, 30 April 2025 – Aker BioMarine today reported its financial results for the first quarter of 2025, delivering solid growth in both revenue and earnings.
Highlights Q1 2025:
“We’re off to a good start in 2025, with growth in both revenue and earnings. Adjusted EBITDA rose 59% year-over-year, reflecting the operational improvements we've made across the business. Our Human Health Ingredients segment continues to be the key growth engine, experiencing demand growth across multiple regions,” said Matts Johansen, CEO of Aker BioMarine.
The Human Health Ingredients segment delivered a strong quarter, with 16% revenue growth driven by rising demand in China, Europe, and South America. Adjusted EBITDA increased 36%, supported by higher volume, improved pricing, and lower unit costs. The segment has now achieved nine consecutive quarters of revenue growth, underscoring consistent performance through operational improvements.
Consumer Health Products returned to year-over-year growth, with revenue up 4% compared to Q1 last year. Sequential decline reflected normal seasonality. Adjusted EBITDA remained positive, supported by ongoing cost discipline, despite slightly lower gross margins. The broader FMCG supplements market grew by approximately 3% in the quarter.
In the Emerging Business segment, revenue remained stable at USD 2.1 million. The segment continues to progress toward cash break-even, with active engagement in new commercial opportunities.
A key strategic milestone in the quarter was the signing of an agreement with KGK Science Inc. to initiate Aker BioMarine’s first clinical trial for Lysoveta, a breakthrough LPC-based supplement targeting brain and eye health. This marks the beginning of clinical development to support future brain-related health claims.
Outlook
The company expects continued growth in Human Health Ingredients, supported by strong demand across markets. In Consumer Health Products, growth has resumed and is expected to follow market trends. Emerging Business remains focused on reaching break-even and pursuing new opportunities.
At the corporate level, Aker BioMarine has implemented a leaner cost base and is executing initiatives to further strengthen financial and operational efficiency. The company remains responsive to macroeconomic uncertainty and new tariffs, and is actively managing productivity and cost measures.
About Aker BioMarine
Aker BioMarine is a leading human health and nutrition innovator that develops krill-derived products for consumer health and nutrition. Krill is a natural, powerful, and health-promoting source of nutrients from the pristine waters of Antarctica, and Aker BioMarine has a unique position in its industry.
The ingredient portfolio consists of Superba Krill Oil, Lysoveta, FloraMarine, and PL+, as well as the consumer brand, Kori Krill. The company’s innovative approach also extends into its spin-offs: AION, which helps reduce and recycle plastic waste across industries, and Understory, a protein brand. Aker BioMarine is listed on the Oslo Stock Exchange (AKBM).